Portia Kit
NDC Package 0555-9020-58
Package Information
Portia (levonorgestrel and ethinyl estradiol) kits is portia® (levonorgestrel and ethinyl estradiol tablets USP) is indicated for use by females of reproductive potential to prevent pregnancy. This formulation utilizes a kit delivery system. Marketed by Teva Pharmaceuticals Usa, Inc., this product is identified by NDC 0555-9020 and is authorized under FDA application ANDA075866.
Identification & Billing
- RxCUI: 238019 - levonorgestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet
- RxCUI: 238019 - ethinyl estradiol 0.03 MG / levonorgestrel 0.15 MG Oral Tablet
- RxCUI: 748797 - inert 1 MG Oral Tablet
- RxCUI: 748797 - inert ingredients 1 MG Oral Tablet
- RxCUI: 748878 - {21 (ethinyl estradiol 0.03 MG / levonorgestrel 0.15 MG Oral Tablet) / 7 (inert ingredients 1 MG Oral Tablet) } Pack
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0555 - Teva Pharmaceuticals Usa, Inc.
- 0555-9020 - Portia
- 0555-9020-58 - 6 POUCH in 1 CARTON / 1 BLISTER PACK in 1 POUCH (0555-9020-79) / 1 KIT in 1 BLISTER PACK
- 0555-9020 - Portia
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0555-9020-58 identifies a specific commercial package of 6 pouch in 1 carton / 1 blister pack in 1 pouch (0555-9020-79) / 1 kit in 1 blister pack of Portia, a human prescription drug labeled by Teva Pharmaceuticals Usa, Inc.. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Teva Pharmaceuticals Usa, Inc. on June 27, 2002. The current certification is valid through December 31, 2026.
How is this Teva Pharmaceuticals Usa, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00555902058. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 6 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.